Quarterly results round-up: Boston swings to loss on goodwill charge, COV, BCR, ROG, ZMH
This article was originally published in Clinica
Boston Scientific has had a poor second fiscal quarter, seeing revenues shrink 7% and swinging to a net loss. Q2 sales were $1.83bn versus $1.98bn during the same period last year, weighed down by declines in the firm's two biggest units, interventional cardiology (-16% to $549m) and cardiac rhythm management (CRM, -10% to $488m). These businesses have been weak for some time – in Q1, sales fell 5% to $603m and 10% to $501m, respectively (www.clinica.co.uk, 20 April 2012).